Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback